India's GlaxoSmithKline Pharma reports profit rise on strong demand

GlaxoSmithKline Pharmaceuticals

13/05/2025 12:40

May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.

The Indian unit of British drugmaker GSK GSK.L reported consolidated profit of 2.63 billion rupees ($30.86 million) in the quarter ended March 31, up 35% year-on-year.

Its revenue from operations climbed about 5% to 9.74 billion rupees.

For further results highlights, click nFWN3RL0SZ

KEY CONTEXT

GlaxoSmithKline Pharma has been benefitting from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Strong demand for its shingles vaccine, Shingrix, has also boosted earnings, the company said.

These have also helped it mitigate the impact of pricing curbs on some of its drugs that have been on the Indian government's essential medicines list since September 2022.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
GlaxoSmithKline Pharmaceuticals Ltd
GLAX.NS
45.82
33.62
9.64
12.65
Buy
4
0.96
1.18
Pfizer Ltd
PFIZ.NS
28.41
21.70
9.21
13.28
Buy
3
0.71
0.82
Aurobindo Pharma Ltd
ARBN.NS
15.86
9.23
10.13
22.60
Buy
23
0.82
0.37
Abbott India Ltd
ABOT.NS
40.52
31.75
7.38
12.64
Strong Buy
5
0.90
1.36

* The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JANUARY TO MARCH STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 85.2150 Indian rupees

GLAX Q4 https://tmsnrt.rs/435Vrex

 (Reporting by Nandan Mandayam in Bengaluru; Editing by Varun H K)

 ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))